China Pharma Holdings, Inc. Comments on Unusual Market Activity
HAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, 2026, the NYSE American has contacted the Company in accordance with its usual...
Angel Yeast’s Initiative Advances Internationally Recognized Codex Standard for baker’s yeast
YICHANG, China, July 21, 2026 /PRNewswire/ -- The 49th session of the Codex Alimentarius Commission (CAC49), held in Geneva, Switzerland, from July 6 to 10, 2026, adopted a number of international food standards, including the Codex Standard for Baker's Yeast, which was proposed by China. The 49th...
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena — Who Is Leading?
T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew notable industry attention: preliminary first-in-human data for MT027, T-MAXIMUM PHARMACEUTICAL Inc's allogeneic universal CAR-T product targeting B7H3, has been accepted...
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis (NCT06712654). The trial is being conducted at multiple clinical sites...
Takeda’s Dengue Vaccine (TAK-003) Becomes India’s First Approved Dengue Vaccine, Bringing Prevention to One of the World’s Most At-Risk Populations
The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against dengue disease and dengue-related hospitalization NEW DELHI,...
Haier Biomedical Presents Digital Blood Management Platform at ISBT Congress 2026, Advancing Its Transition from Equipment Provider to Full-Process Solution Partner
Driving Digital Transformation in Blood Management for Plasma Collection Centers, Hospitals, and Blood Bank Centers KUALA LUMPUR, Malaysia, July 21, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) participated at the ISBT Congress 2026 in Kuala Lumpur, presenting its blood product portfolio and integrated workflow solutions to the global transfusion market. This...
MALAYSIA HEALTHCARE BROUGHT MALAYSIA’S LEADING HOSPITALS TO HONG KONG’S MOST INFLUENTIAL HEALTHCARE AUDIENCE
HONG KONG, July 21, 2026 /PRNewswire/ -- As healthcare travellers place increasing importance on trust, quality, and patient experience, Malaysia Healthcare Travel Council (MHTC), under the Malaysia Healthcare brand, successfully concluded MH Week Hong Kong 2026 as part of the Malaysia Year of Medical Tourism 2026 (MYMT 2026) campaign themed Healing...
Ping An Unveils Innovative AI Solutions in Healthcare, Insurance and Payments at WAIC 2026
HONG KONG and SHANGHAI, July 21, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group"; HKEX: 2318; SSE: 601318) unveiled a range of innovative artificial intelligence (AI) products and services at the World Artificial Intelligence Conference 2026 (WAIC 2026). Spanning healthcare, insurance and payments scenarios, these innovations further advance AI-driven development of Ping An's "integrated finance...
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing...
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
SHANGHAI, July 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain, October 23-27, 2026. Oral...
